Chugai Deploys Phylo’s Biomni Lab AI Agents Across Drug Discovery

본문 미리보기

Phylo, Inc. announced on August 4, 2026 that Chugai Pharmaceutical Co., Ltd. will deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's drug discovery workflows, covering four areas: single-cell analysis, human genetics, disease biology, and target evaluation. The Tokyo-based drugmaker, a Roche Group member listed on the Tokyo Stock Exchange's Prime Market, joins what Phylo calls its founding group of customers for the platform. Under the collaboration, Biomni…